Author/Authors :
Hami, Maryam Kidney Transplantation Complications Research Center - Mashhad University of Medical Sciences - Mashhad, Iran , Bigdeli, Amir Bojnourd University of Medical Sciences - Bojnourd, Iran , Khameneh-Bagheri, Ramin School of Medicine - Mashhad University of Medical Sciences - Mashhad, Iran , Rajabi, Omid Mashhad University of Medical Sciences - Mashhad, Iran , Salehi, Maryam Mashhad University of MedicalSciences - Mashhad, Iran , Zahedi-Avval, Farnaz Ghaem Hospital - School of Medicine - Mashhad University of Medical Sciences - Mashhad, Iran
Abstract :
Contrast-induced nephropathy (CIN) is the most
common cause of iatrogenic acute kidney injury, happens more
commonly in patients with underlying kidney diseases. It has been
shown that oxidative stress is the main mechanism of contrast
nephropathy. Curcumin is suggested as an herbal antioxidant agent,
thus we decided to assess the effect of curcumin in preventing this
complication in patients with underlying chronic kidney disease
who need coronary angiography.
Methods. We conducted double blind, placebo-controlled clinical
trial in 60 moderate to severe CKD patients who underwent
coronary angiography or angioplasty. Adjusted dose of Iodixanol
was used as contrast agent in all of them. Curcumin or placebo
administered orally, 1.5 g daily from 2 days before procedure to
3 days after it. CIN was defined by an increased serum creatinine
≥ 0.3 mg/dL or an increase to ≥ 1.5 times of the baseline within
48 hours after procedure.
Results. CIN occurred in 12 (20%) of patients, 5 (16.7%) in Curcumin
group and 7 (23.3%) in placebo group (OR = 0.56, 95% CI = 0.18
to 2.36; P > .05). Serum Creatinine was increased after 72 hours
of intervention from 1.65 ± 0.26 mg/dL to 1.79 ± 0.33 mg/dL in
Curcumin group and from 1.61 ± 0.23 mg/dL to 1.86 ± 0.35 in
placebo group. No significant difference was seen between the
mean increase of serum creatinine in two groups (difference of
0.006 mg/dL, 95% CI = - 0.06 to 0.08; P > .05).
Conclusion. Prophylactic oral Curcumin could not show protective
effects on CIN in high-risk patients who have undergone coronary
procedures.